rs186021206 — ASGR1

Intergenic tag SNP 7.3 kb downstream of ASGR1; the rare A allele proxies the ASGR1 del12 loss-of-function variant (r²=0.86) and associates with ~13 mg/dL lower non-HDL cholesterol and a 34% reduced risk of coronary artery disease

See your personal result for ASGR1

Upload your DNA data to find out which genotype you carry and what it means for you.

Upload your DNA data

Works with 23andMe, AncestryDNA, and other DNA test exports. Results in under 60 seconds.

ASGR1 — The Liver's Cholesterol Clearance Switch

Most people have never heard of the asialoglycoprotein receptor, but a rare natural experiment in human genetics has made it one of cardiology's most watched drug targets. The ASGR1 gene11 ASGR1 gene
encodes the major subunit of the asialoglycoprotein receptor, a liver-specific lectin that clears desialylated glycoproteins from circulation via clathrin-mediated endocytosis sits on chromosome 17. Scattered among the population are individuals who carry a rare 12-base-pair deletion in intron 4 of this gene — and they are, on average, living with lower non-HDL cholesterol and a 34% lower risk of coronary artery disease. The SNP rs186021206, an intergenic variant 7.3 kilobases downstream of ASGR1, is the strongest proxy marker for this deletion with a correlation of r² = 0.86.

The Mechanism

ASGR1's role in cholesterol metabolism is indirect but potent. When the receptor is functional, it binds asialoglycoproteins and delivers them to lysosomes for degradation. The amino acids released from this process activate lysosomal mTORC1, which in turn suppresses AMPK — the cell's energy sensor. AMPK normally stabilizes LXRα, a transcription factor that drives expression of the ABCA1 and ABCG5/G8 cholesterol transporters (which export cholesterol to bile). Simultaneously, AMPK suppresses SREBP1, a master regulator of lipogenesis. Loss of ASGR1 function breaks this chain: reduced lysosomal amino acid flux → mTORC1 inhibition → AMPK activation → LXRα stabilization → increased cholesterol excretion + reduced de novo synthesis22 reduced lysosomal amino acid flux → mTORC1 inhibition → AMPK activation → LXRα stabilization → increased cholesterol excretion + reduced de novo synthesis
Wang et al. Nature 2022: anti-ASGR1 antibody treatment demonstrated the full pathway and showed synergistic lipid lowering with atorvastatin and ezetimibe. Separately, ASGR1 also acts as a PCSK9-independent ligand for the hepatic LDL receptor, and its loss is associated with increased LDLR surface expression.

rs186021206 itself lies in an unannotated intergenic region between two long non-coding RNA loci. It carries no direct functional annotation. After statistical adjustment for the del12 variant, rs186021206 loses its association with non-HDL cholesterol — confirming it as a proxy marker for the del12 causal allele, not an independent functional variant.

The Evidence

The landmark study came from the deCODE genetics group in Iceland: Nioi et al., NEJM 2016 (PMID 27192541)33 Nioi et al., NEJM 2016 (PMID 27192541)
sequenced 2,636 Icelanders and tested associations across 33,090 CAD cases and 236,254 controls. Among seven SNPs correlated with the del12 deletion, rs186021206 showed the strongest association — a reduction in non-HDL cholesterol of 12.9 mg/dL (95%CI: 8.7–17.1, p = 1.4×10⁻⁹) in heterozygous A-allele carriers. When the del12 variant itself was tested directly (in carriers identified by sequence data), the reduction reached 15.3 mg/dL (95%CI: 11.7–18.9) across Iceland, Netherlands, and Denmark combined. CAD risk was reduced by 34%: combined OR 0.66 (95%CI: 0.55–0.79, p = 4.0×10⁻⁶).

A 2020 replication study Sanna et al. Atherosclerosis 2020 (PMID 32679274)44 Sanna et al. Atherosclerosis 2020 (PMID 32679274)
studied three common ASGR1 locus variants in UK Biobank found CAD/MI risk reduction of 23% per 10 mg/dL reduction in LDL-C (OR 0.77, 95%CI: 0.62–0.96) with no evidence of pleiotropic effects — the entire cardiovascular benefit appears to be explained by the LDL-lowering alone.

A Mendelian randomization study using rs186021206 as the genetic instrument Nioi et al. 2023 (PMID 36585392)55 Nioi et al. 2023 (PMID 36585392) estimated 3.31 additional life-years per standard-deviation reduction in LDL-C (95%CI: 1.01–5.62) from genetically mimicked ASGR1 inhibition, with beneficial effects on apolipoprotein B, triglycerides, and CRP.

In a large-animal validation66 large-animal validation
Murata et al. eLife 2021 (PMID 34762653): ASGR1-deficient pigs showed reduced serum LDL-C, less atherosclerotic plaque, and higher hepatic LDLR expression, closely mirroring the human genetic findings, ASGR1-deficient pigs recapitulated the human lipid phenotype with reduced atherosclerosis, providing strong biological validation.

The variant is more common in Europeans (~0.69%) and rare in Africans (~0.14%), with essentially no representation in East Asian or South Asian populations. This European enrichment likely reflects the Icelandic founder population in which del12 was first discovered.

Practical Actions

For A-allele carriers at this locus, the non-HDL-C reduction (~13 mg/dL) is a genuine, genetically encoded cardiovascular benefit. This does not mean further lipid optimization is irrelevant — it means the baseline risk is lower than for non-carriers with otherwise similar risk profiles. Carriers should still have fasting lipid panels to confirm the expected non-HDL-C advantage is present. The protective effect operates through hepatic cholesterol clearance, not through pathways affected by diet or exercise.

Emerging ASGR1 inhibitors (anti-ASGR1 antibodies) show LDL-C lowering that mirrors the genetic findings and synergizes with existing lipid-lowering therapies. This is an active therapeutic development area, but no approved drugs exist yet.

Interactions

rs186021206 functions as a proxy for ASGR1 del12. Two other SNPs at the same locus — rs55714927 and rs150688657 — have been used as genetic instruments for ASGR1 function in Mendelian randomization analyses. The cholesterol-lowering effect of ASGR1 haploinsufficiency appears to be additive with statin therapy: in cell-based and animal models, anti-ASGR1 antibodies combined with atorvastatin produced greater LDL-C reduction than either alone, consistent with complementary mechanisms (ASGR1 increases cholesterol excretion; statins decrease de novo synthesis).

Genotype Interpretations

What each possible genotype means for this variant.

GG Normal

Standard ASGR1 function — no inherited non-HDL cholesterol advantage

You carry two copies of the G allele at rs186021206, the common genotype found in approximately 99% of people globally. This is the reference state: your ASGR1 gene is fully functional, and you do not carry the genetic advantage associated with ASGR1 haploinsufficiency. Your non-HDL cholesterol and coronary artery disease risk are not reduced by this variant. Standard cardiovascular risk management applies.

AG ASGR1 Haploinsufficiency Carrier Beneficial

One copy of the protective A allele — reduced non-HDL cholesterol and lower coronary artery disease risk

The ASGR1 del12 variant (which rs186021206 proxies) activates a cryptic splice site in ASGR1 intron 4, causing a frameshift and a premature stop codon. The resulting truncated protein is degraded, effectively creating a heterozygous loss-of-function state. With one functional copy, the asialoglycoprotein receptor still operates but at reduced capacity.

The reduced receptor activity has a cascade effect on hepatic cholesterol handling: less endocytic flux through ASGR1 means reduced lysosomal amino acid delivery, which inhibits mTORC1 and activates AMPK. Active AMPK stabilizes LXRα (increasing ABCG5/G8-mediated cholesterol excretion to bile) and suppresses SREBP1 (reducing lipogenesis). The net effect is lower plasma non-HDL cholesterol and lower LDL-C.

Importantly, the 34% CAD risk reduction is fully explained by the LDL-C reduction — there are no pleiotropic cardiovascular effects independent of lipid lowering (Sanna et al. 2020). This means the protection is real but proportional: the ~13 mg/dL non-HDL-C advantage translates to the expected risk benefit, with no bonus cardiovascular effects.

Note that rs186021206 is a proxy SNP, not the causal variant. If your genome data comes from WGS, the del12 variant itself (or a direct test) would be more informative. For consumer chip data, rs186021206 is not typically genotyped due to its rarity.

AA ASGR1 Homozygous Protective Carrier Beneficial

Two copies of the protective A allele — maximal genetically conferred non-HDL cholesterol reduction (extremely rare)

Because rs186021206 AA homozygosity is so rare (estimated frequency ~0.002%), there are no published studies specifically characterizing this genotype. The expectation from ASGR1 biology is that homozygous loss-of-function would produce greater cholesterol lowering than heterozygosity, consistent with the mechanism (both receptor subunits reduced). ASGR1-null pigs showed a clear reduction in LDL-C and atherosclerosis without apparent toxicity (Murata et al. eLife 2021), and animal models of complete ASGR1 deletion have not revealed adverse metabolic or hepatic phenotypes. However, ASGR1 is also used as an entry point by hepatitis B virus and SARS-CoV-2 — theoretical considerations about susceptibility to these pathogens exist but have not been clinically validated for partial or complete loss-of-function states.

Mildly elevated alkaline phosphatase (ALP) and serum vitamin B12 have been reported in del12 carriers — these are expected off-target effects of reduced asialoglycoprotein clearance and are not clinically concerning at heterozygous levels. AA homozygotes may show more pronounced elevations.